Stephens Consulting’s Veracyte VCYT Stock Holding History

Stephens Consulting’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$593	–	1987
2025 Q1	$593	Buy	+20	New	+$762	﹤0.01%	888

Other funds holding VCYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's VCYT Position: Q2 2025 in Review

Stephens Consulting sold out of Veracyte (VCYT) in Q2 2025, closing a stake of 20 shares — an estimated $593 sold.

Stephens Consulting first reported a position in VCYT in Q1 2025 and held it in 1 quarter. The position peaked at $593 in Q1 2025. 278 funds tracked by Wall St. Rank hold VCYT as of Q2 2025.

Stephens Consulting reported no remaining Veracyte position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 20 Veracyte shares in Q2 2025, an estimated $593.
Stephens Consulting first reported a position in Veracyte in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Veracyte position peaked at $593 in Q1 2025.
278 funds tracked by Wall St. Rank held Veracyte as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.